Axial Spondyloarthritis
Axial Spondyloarthritis Market

Axial Spondyloarthritis (axSpA) is an inflammatory disease of the axial skeleton associated with

significant pain and disability. Axial spondyloarthritis is an umbrella term and it includes Ankylosing Spondylitis (AS) where changes to the sacroiliac joints or the spine can be seen on x-ray.


Axial Spondyloarthritis Epidemiology Segmentation 


  • Total prevalent cases of Axial Spondyloarthritis 
  • Total diagnosed Axial Spondyloarthritis prevalent cases 
  • Gender-specific diagnosed Axial Spondyloarthritis prevalent cases
  • Age-specific diagnosed Axial Spondyloarthritis prevalent cases
  • Gene-specific diagnosed Axial Spondyloarthritis prevalent cases 


Axial Spondyloarthritis Epidemiological Insights Observed in 2020


  • The total prevalent population of Axial Spondyloarthritis was observed to be 3,122,331.
  • The most prevalent age group was 40 to 49 years for Axial Spondyloarthritis.
  • The total prevalent population of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) was found to be 1,821,360.
  • The total prevalent population of Ankylosing Spondylitis was 1,300,971.
  • The prevalent population of Ankylosing Spondylitis showed a male predominance, whereas nr-axSpA showed a female predominance.


Axial Spondyloarthritis Market Insight


The market size of Axial Spondyloarthritis in the United States was found to be USD 4,716 million in 2020. 


Axial Spondyloarthritis Market Drivers


  • The introduction of novel products
  • Increasing prevalence
  • Awareness about the disease
  • Research and development strategies


Axial Spondyloarthritis Market Barriers


  • High-cost treatment
  • Delay in diagnosis
  • Immunogenicity
  • Loss of patent exclusivity
  • Availability of generics


Axial Spondyloarthritis Emerging Drugs


The emerging drugs of the Axial Spondyloarthritis market are

  • Tofacitinib
  • Bimekizumab
  • Ilumya (Tildrakizumab)
  • Namilumab
  • ILT-101(Interleukin 2)
  • Brodalumab (KHK4827)
  • Rinvoq (Upadacitinib)
  • Filgotinib, and several others


Axial Spondyloarthritis Key Players 


The key players working in the Axial Spondyloarthritis market are


  • Pfizer
  • UCB Biopharma
  • Sun Pharma Global
  • Izana Bioscience
  • Iltoo Pharma
  • Kyowa Kirin
  • AbbVie
  • Galapagos
  • Gilead, and several others.